OmniAb Names Amechi Nwachuku Chief Operating Officer
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it
OABI - OmniAb, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$4.00
DETAILS
HIGH:
$4.00
LOW:
$4.00
MEDIAN:
$4.00
CONSENSUS:
$4.00
UPSIDE:
84.25%
Stock News
OmniAb Names Amechi Nwachuku Chief Operating Officer
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb's proprietary, innovative high-throu.
OmniAb Q1 Earnings Call Highlights
OmniAb NASDAQ: OABI reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated milestone revenue. Get OmniAb alerts:Sign UpPartner program progress drives revenue outperformance President and CEO Matt Foehr said the company continues to see partner programs derived from OmniAb's technologies move into the clinic and into later-stage development, which he described as the point where the licensing model translates into “clearer and more visible value” through potential future milestones and royalties.
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance. “OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidanc.
OmniAb to Participate in Three Upcoming Investor Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences over the coming weeks. H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, May 6. Management will participate in a fireside chat on Wednesday, May 6th. Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28. Management will hold virtual one-on-one and small group meetings with investors on Thursday, May 28th. Jeff.
OmniAb to Report First Quarter 2026 Financial Results on May 7
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on Thursday, May 7, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss first quarter 2026 financial results and business updates Date: Thursday, May 7, 2026 Time: 4:30 p.m. Easter.
Matthew Foehr Sells 19,244 Shares of OmniAb (NASDAQ:OABI) Stock
OmniAb, Inc. (NASDAQ: OABI - Get Free Report) CEO Matthew Foehr sold 19,244 shares of the business's stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $1.49, for a total value of $28,673.56. Following the completion of the transaction, the chief executive officer owned 4,420,492 shares of the
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.12 per share a year ago.
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. “OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, se.
OmniAb (OABI) Projected to Post Earnings on Wednesday
OmniAb (NASDAQ: OABI - Get Free Report) is expected to be releasing its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $9.0030 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning
OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss fourth quarter 2025 financial results and business updates Date: Wednesday, March 4, 2026 Time: 4:.